跳至主要内容
临床试验/TCTR20210526006
TCTR20210526006尚未招募不适用

Safety and Efficiency of Angiotensin II Receptor Blockers (ARBs) in Diabetic Patients with Advanced Chronic Kidney Disease

Division of Nephrology, Department of Internal Medicine, Thammasat University Hospital0 个研究点目标入组 165 人开始时间: 2021年5月26日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
165

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • Patients with diabetes mellitus and advanced CKD, defines as estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73m2 will be included. The patients who newly start treatment with any ARBs during eGFR less than 30 ml/min/1.73m2 will be compared with patients who do not receive any ACEi/ARBs.

排除标准

  • 1. age of < 18 years old, 2. eGFR < 6 ml/min/1.73 m2, 3. currently on renal replacement therapy, 4. patients who have currently received ACEi/ARBs before the cohort entry, 5. patients whose medical data could not be accessed.

研究者

发起方
Division of Nephrology, Department of Internal Medicine, Thammasat University Hospital

相似试验